179174-80-2

Upstream product

• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 
• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 162011-83-8 3-(3,4-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one 

Downstream Products

• 885020-48-4 (2Z)-4-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,4-difluorophenyl)-2-[4-(methylsulfonyl)phenyl]but-2-en-1-ol 
• 179174-81-3 (2Z)-3-(3,4-difluorophenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]but-2-en-1-yl acetate 
• 179174-83-5 (2Z)-4-(acetoxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-enoic acid 
• 179174-82-4 (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenal 

Relevant academic research and scientific papers

Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia

A water soluble choline prodrug (17) of a COX-2 selective inhibitor (16) suitable for intravenous dosing in models of cerebral ischemia has been developed. Constant infusion studies using 17 demonstrate that extrapolated brain levels of 16 may be maintained for over 24 h in rats.

WATER SOLUBLE PRODRUGS OF COX-2 INHIBITORS

Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them.

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.